Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1869458
                    [Title] => Strong evidence links obesity to gastrointestinal, breast cancers
                    [Summary] => There is strong evidence linking adiposity to esophageal adenocarcinoma, multiple myeloma, and cancer of the colon, rectum, biliary tract, pancreas, endometrium, kidney, and postmenopausal breast, according to the authors of an umbrella review published in the Feb. 28 edition of BMJ.
                    [DatePublished] => 2018-11-18 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 902524
                    [Title] => DOH probing anthrax cases in Abra
                    [Summary] => 
Disease experts of the Department of Health (DOH) are now investigating suspected cases of “cutaneous anthrax” in Lagangilang, Abra.

                    [DatePublished] => 2013-01-30 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 1804896
                    [AuthorName] => Sheila Crisostomo
                    [SectionName] => Nation
                    [SectionUrl] => nation
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 557484
                    [Title] => Coronaviruses cause GI illness
                    [Summary] => 
Two types of newly recognized coronavirus were identified in stool samples of patients with gastrointestinal disease, and more than half of those patients also had respiratory symptoms, based on data from more than 400 adults and children.
                    [DatePublished] => 2010-03-14 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 442544
                    [Title] => Endoscopy: A clear view inside the body
                    [Summary] => 
Do you have difficulty swallowing or are you experiencing constant vomiting or nausea?
                    [DatePublished] => 2009-02-24 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 225508
                    [Title] => New French compound  bolsters NSAID benefits,  suppresses adverse side effects?
                    [Summary] => Clinicians may have at their disposal a new type of medication that effectively relieves pain, but without the troubling gastrointestinal side effects –  including peptic ulcers and bleeding – caused by nonsteroidal anti-inflammatory drugs. NicOx, a pharmaceutical company based in France, is in the process of developing anti-inflammatory drugs (NSAIDS) with nitrix oxide.


                    [DatePublished] => 2003-10-26 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 181173
                    [Title] => Good News For Runners: Less ‘wear’ on joints, delayed disabilities
                    [Summary] => SORRENTO, Italy – New research among long-distance runners shows that osteoarthritis (OA), often called "wear and tear" arthritis, is not caused by "wear" alone.


At a symposium sponsored by Boehringer Ingelheim here last week, Prof. Jim Fries, of Stanford University, USA, presented new data showing that long-distance runners in the study actually developed disability much more slowly than non-exercisers. They reached a given level of disability 12 years later in life than non-exercisers, and enjoyed regular pain-free activity.


                    [DatePublished] => 2002-10-24 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 162433
                    [Title] => ‘Smart tablet’ effective in cancers
                    [Summary] => Data presented at the recent 38th annual meeting of the American Society for Clinical Oncology (ASCO) showed that Xeloda (capecitabine), Roche’s new oral tumor-activated chemotherapy treatment, is highly effective at treating gastrointestinal cancers – colorectal, stomach and oesophageal. 


Various study results presented at the ASCO meeting showed that the oral Xeloda has the potential to effectively replace the current standard treatment, intravenous (iv) 5-FU, in gastrointestinal cancers.


                    [DatePublished] => 2002-05-27 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

gastrointestinal

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1869458
                    [Title] => Strong evidence links obesity to gastrointestinal, breast cancers
                    [Summary] => There is strong evidence linking adiposity to esophageal adenocarcinoma, multiple myeloma, and cancer of the colon, rectum, biliary tract, pancreas, endometrium, kidney, and postmenopausal breast, according to the authors of an umbrella review published in the Feb. 28 edition of BMJ.
                    [DatePublished] => 2018-11-18 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 902524
                    [Title] => DOH probing anthrax cases in Abra
                    [Summary] => 
Disease experts of the Department of Health (DOH) are now investigating suspected cases of “cutaneous anthrax” in Lagangilang, Abra.

                    [DatePublished] => 2013-01-30 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 1804896
                    [AuthorName] => Sheila Crisostomo
                    [SectionName] => Nation
                    [SectionUrl] => nation
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 557484
                    [Title] => Coronaviruses cause GI illness
                    [Summary] => 
Two types of newly recognized coronavirus were identified in stool samples of patients with gastrointestinal disease, and more than half of those patients also had respiratory symptoms, based on data from more than 400 adults and children.
                    [DatePublished] => 2010-03-14 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 442544
                    [Title] => Endoscopy: A clear view inside the body
                    [Summary] => 
Do you have difficulty swallowing or are you experiencing constant vomiting or nausea?
                    [DatePublished] => 2009-02-24 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 225508
                    [Title] => New French compound  bolsters NSAID benefits,  suppresses adverse side effects?
                    [Summary] => Clinicians may have at their disposal a new type of medication that effectively relieves pain, but without the troubling gastrointestinal side effects –  including peptic ulcers and bleeding – caused by nonsteroidal anti-inflammatory drugs. NicOx, a pharmaceutical company based in France, is in the process of developing anti-inflammatory drugs (NSAIDS) with nitrix oxide.


                    [DatePublished] => 2003-10-26 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 181173
                    [Title] => Good News For Runners: Less ‘wear’ on joints, delayed disabilities
                    [Summary] => SORRENTO, Italy – New research among long-distance runners shows that osteoarthritis (OA), often called "wear and tear" arthritis, is not caused by "wear" alone.


At a symposium sponsored by Boehringer Ingelheim here last week, Prof. Jim Fries, of Stanford University, USA, presented new data showing that long-distance runners in the study actually developed disability much more slowly than non-exercisers. They reached a given level of disability 12 years later in life than non-exercisers, and enjoyed regular pain-free activity.


                    [DatePublished] => 2002-10-24 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 162433
                    [Title] => ‘Smart tablet’ effective in cancers
                    [Summary] => Data presented at the recent 38th annual meeting of the American Society for Clinical Oncology (ASCO) showed that Xeloda (capecitabine), Roche’s new oral tumor-activated chemotherapy treatment, is highly effective at treating gastrointestinal cancers – colorectal, stomach and oesophageal. 


Various study results presented at the ASCO meeting showed that the oral Xeloda has the potential to effectively replace the current standard treatment, intravenous (iv) 5-FU, in gastrointestinal cancers.


                    [DatePublished] => 2002-05-27 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Strong evidence links obesity to gastrointestinal, breast cancers

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | November 18, 2018 - 12:00am

There is strong evidence linking adiposity to esophageal adenocarcinoma, multiple myeloma, and cancer of the colon, rectum, biliary tract, pancreas, endometrium, kidney, and postmenopausal breast, according to the...

Opinion

DOH probing anthrax cases in Abra

By Sheila Crisostomo | January 30, 2013 - 12:00am

Disease experts of the Department of Health (DOH) are now investigating suspected cases of “cutaneous anthrax” in Lagangilang, Abra.

Nation

Coronaviruses cause GI illness

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | March 14, 2010 - 12:00am

Two types of newly recognized coronavirus were identified in stool samples of patients with gastrointestinal disease, and more than half of those patients also had respiratory symptoms, based on data from more than...

Opinion

Endoscopy: A clear view inside the body

February 24, 2009 - 12:00am

Do you have difficulty swallowing or are you experiencing constant vomiting or nausea?

Health And Family

New French compound bolsters NSAID benefits, suppresses adverse side effects?

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | October 26, 2003 - 12:00am

Clinicians may have at their disposal a new type of medication that effectively relieves pain, but without the troubling gastrointestinal side effects – including peptic ulcers and bleeding – caused by...

Opinion

Good News For Runners: Less ‘wear’ on joints, delayed disabilities

October 24, 2002 - 12:00am

SORRENTO, Italy – New research among long-distance runners shows that osteoarthritis (OA), often called "wear and tear" arthritis, is not caused by "wear" alone. At a symposium sponsored...

Science and Environment

‘Smart tablet’ effective in cancers

May 27, 2002 - 12:00am

Data presented at the recent 38th annual meeting of the American Society for Clinical Oncology (ASCO) showed that Xeloda (capecitabine), Roche’s new oral tumor-activated chemotherapy treatment, is highly effective...

Science and Environment